| 刊名 | Medicinal Plant |
| 作者 | Yiting CHAI, Yafang LIU, Fanfan SUN, Xiaofei FENG |
| 作者单位 | Affiliated Hospital of Changzhi Academy of Traditional Chinese Medicine Research |
| DOI | DOI:10.19600/j.cnki.issn2152-3924.2026.05.012 |
| 年份 | 2026 |
| 刊期 | 5 |
| 页码 | 70-72,77 |
| 关键词 | Qingqiao Dingxuan Decoction, Residual symptoms after canalith repositioning, Phlegm-stasis obstructing orifices |
| 摘要 | [Objectives] To investigate the efficacy and safety of the self-formulated Qingqiao Dingxuan Decoction in treating residual symptoms after canalith repositioning and to summarize the experience of TCM pattern differentiation. [Methods] Sixty patients with residual symptoms after successful canalith repositioning were selected from August 2023 to July 2025 and randomly divided into a treatment group and a control group, with 30 patients in each group. The treatment group received orally administered self-formulated Qingqiao Dingxuan Decoction, while the control group received orally administered Betahistine Mesilate Tablets. The Dizziness Assessment Rating Scale (DARS) scores, recurrence rate, and safety were compared between the two groups before and after treatment. [Results] At the 14-day post-treatment assessment and the 1-month follow-up, the DARS scores of both groups were significantly lower than before treatment. Furthermore, the scores of the treatment group were consistently lower than those of the control group, with statistically significant differences (P<0.05). The recurrence rate was 0% in the treatment group and 3.33% in the control group. No serious adverse events occurred in either group. [Conclusions] Qingqiao Dingxuan Decoction demonstrates definite efficacy and good safety in treating residual symptoms after canalith repositioning. It can effectively improve vertigo symptoms and promote vestibular function recovery. |